Koss Olinger Consulting LLC Takes $235,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Koss Olinger Consulting LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 370 shares of the biopharmaceutical company’s stock, valued at approximately $235,000.

A number of other large investors also recently made changes to their positions in the stock. Marietta Wealth Management LLC increased its position in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company’s stock valued at $6,836,000 after buying an additional 2,501 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after buying an additional 814,713 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock valued at $16,255,000 after buying an additional 955 shares in the last quarter. KBC Group NV increased its position in shares of Regeneron Pharmaceuticals by 9.4% in the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company’s stock valued at $94,779,000 after buying an additional 12,793 shares in the last quarter. Finally, Lmcg Investments LLC increased its position in shares of Regeneron Pharmaceuticals by 231.3% in the 1st quarter. Lmcg Investments LLC now owns 14,481 shares of the biopharmaceutical company’s stock valued at $9,184,000 after buying an additional 10,110 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $563.00 on Monday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The stock has a market capitalization of $59.67 billion, a price-to-earnings ratio of 14.19, a PEG ratio of 1.91 and a beta of 0.33. The business has a 50-day moving average of $536.80 and a 200-day moving average of $598.52. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the business posted $11.56 EPS. Regeneron Pharmaceuticals’s revenue was up 3.6% on a year-over-year basis. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be given a dividend of $0.88 per share. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on REGN. Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a “buy” rating in a research report on Friday, August 1st. UBS Group restated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. JPMorgan Chase & Co. lowered their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating for the company in a research report on Monday, June 9th. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $841.30.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.